David Pascoe

David Pascoe started the Rosacea Support Group in October 1998.

DFD-29 set to be approved on Nov 4 2024

DFD-29 set to be approved on Nov 4 2024

News today that Journey Medical Corporation is looking forward to having their Oracea competitor, still known as DFD-29, approved by the FDA before the end of the year. Having accepted the New Drug Application, the FDA is now in the final stages of approving this new 40mg minocycline that is showing promise as a treatment […]

Continue Reading

Cyclosporine as a treatment for neurogenic rosacea

Written by on January 11, 2024 in Neurogenic Rosacea, Ocular Rosacea with 0 Comments
Cyclosporine as a treatment for neurogenic rosacea

There has been some relatively recent research into a possible variant of rosacea called neurogenic rosacea. Different from typical rosacea, papules, pustules, and swelling changes are not present in this group of patients. This short correspondences from DermatologicaSinica, the journal of the Dermatological Association of Taiwan documents 3 cases where patients with possible neurogenic rosacea […]

Continue Reading

DFD-29 on it’s way, now has an NDA

Written by on January 10, 2024 in Minocycline, New Rosacea Treatments, tetracyclines with 0 Comments
DFD-29 on it’s way, now has an NDA

Journey Medical’s modified released 40mg minocycline (still code named DFD-29) has published positive Phase 3 Clinical Trial data and is now sitting waiting on a New Drug Application. The company press release touts the combination treatment for both the inflammatory lesions and the redness of rosacea. By comparison, Oracea, the competing product that DFD-29 claims […]

Continue Reading

Everything new and emerging for rosacea

Written by on December 28, 2023 in clinical trials, New Rosacea Treatments with 0 Comments
Everything new and emerging for rosacea

Dermatology and Therapy has published a lengthy article detailing emerging therapies that are on the horizon for rosacea sufferers. It may seem like new and promising treatments for rosacea are few and far between. In recent years we have seen Mirvaso, Rhofade and Soolantra approved and make their way to rosacea sufferers. More recently Zilxi […]

Continue Reading

State of the art in rosacea topical treaments

Written by on December 14, 2023 in research, Rosacea Topicals with 0 Comments
State of the art in rosacea topical treaments

A really easy to access article in Mol. Pharmaceutics has given us a detailed run down of the current status of rosacea topicals and a glimpse into the future of topical treatments. Rosacea Topical Treatment and Care: From Traditional to New Drug Delivery Systems Mol. Pharmaceutics 2023, 20, 8, 3804–3828 https://doi.org/10.1021/acs.molpharmaceut.3c00324 The paper lists the […]

Continue Reading

Top

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.